Safety and Patient Satisfaction With GLASH VISTA (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Bimatoprost (Primary)
- Indications Hypotrichosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allergan
- 24 Jul 2017 Planned End Date changed from 1 Jun 2018 to 8 Jun 2018.
- 24 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 8 Jun 2018.
- 24 Jul 2017 Status changed from recruiting to active, no longer recruiting.